A Look Back at an Exciting 2024 LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / 2024 has been an incredible year for Genflow as we advance our mission to develop novel therapeutics that ...
Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...
Adams is going on the offensive in the coming weeks: he plans to demand changes to the state’s controversial bail reform laws and pointedly remind voters that his most well-known possible challenger — ...